Dr. Robert K. Barnett, M.D.
Gastroenterology (Gastroenterology Physician)
1393 E Sego Lily Dr
Sandy, UT 84092
Who else practices at this address →
Salt Lake County includes primary care (36% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Texas Tech University Health Science Center School of Medicine (1987)
- Years since graduation
- 39
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 183
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1987Medical school: Texas Tech University Health Science Center School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
UT license 178580-1205
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Intermountain Health Riverton Hospital Riverton, UT
- Intermountain Health Alta View Hospital Sandy, UT
- St Mark's Hospital Salt Lake City, UT
Medical groups
- Utah Gastroenterology LLC (69 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 183
- Services billed
- 287
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 52 | 52 |
| Biopsy of large bowel using a flexible endoscope | 50 | 50 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 44 | 43 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 35 | 35 |
| Established patient office or other outpatient visit, 30-39 minutes | 28 | 24 |
| Established patient office or other outpatient visit, 20-29 minutes | 25 | 21 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 15 | 15 |
| Dilation of esophagus | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Pantoprazole Sodium Other prescribers in Sandy, UT | 131 |
| Famotidine Other prescribers in Sandy, UT | 42 |
| Linzess (linaclotide) Other prescribers in Sandy, UT | 35 |
| Lansoprazole Other prescribers in Sandy, UT | 24 |
| Dicyclomine Hcl Other prescribers in Sandy, UT | 24 |
| Omeprazole Other prescribers in Sandy, UT | 24 |
| Metronidazole Other prescribers in Sandy, UT | 19 |
| Stelara (ustekinumab) | 18 |
| Rabeprazole Sodium Other prescribers in Sandy, UT | 16 |
| Mesalamine Other prescribers in Sandy, UT | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 30 payments worth $504 in total to this clinician.
| AbbVie Inc. | $267 |
|---|---|
| Janssen Biotech, Inc. | $59.54 |
| Pfizer Inc. | $47.74 |
| Regeneron Healthcare Solutions, Inc. | $21.22 |
| Takeda Pharmaceuticals U.S.A., Inc. | $19.68 |
| Ardelyx, Inc. | $19.47 |
| Genzyme Corporation | $19.19 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.79 |
| Food and Beverage | $504 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $207,518 in research payments for these studies, mostly to the institutions running them.
- A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
Sanofi US Services Inc. · Active, not recruiting · NCT06557772 - Roche Cancer Screening Collection Study
Genentech, Inc. - A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
Eli Lilly and Company · Active, not recruiting · NCT05556512 - EoE-201
Phathom Pharmaceuticals, Inc. - A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Eli Lilly and Company · Recruiting · NCT07165028
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.